Skip to main content
    S

    Sarepta Therapeutics Inc (SRPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.13
    -0.94 (-5.85%)

    Market Cap: $1.72B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sarepta Therapeutics Inc (SRPT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Sarepta Therapeutics reported revenue of $2.20B for the fiscal year ended Dec 31, 2025, up 15.6% from the year before. That year, net income was -$713.41M with a net margin of -32.5%, operating cash flow was -$205.48M and free cash flow was -$307.45M. The quarter ended Sep 30, 2026 had revenue of $381.35M and net income of -$28.46M.

    Revenue and Margins

    The operating margin was -31.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $5.42M, a compound annual rate of 94.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.20B+15.6%100.0%-31.8%-32.5%
    Dec 2024$1.90B+53.0%100.0%11.5%12.4%
    Dec 2023$1.24B+33.3%100.0%-21.5%-43.1%
    Dec 2022$933.01M+32.9%100.0%-57.5%-75.4%
    Dec 2021$701.89M+30.0%100.0%-65.5%-59.7%
    Dec 2020$540.10M+41.8%100.0%-104.5%-102.6%
    Dec 2019$380.83M+26.5%100.0%-185.3%-187.8%
    Dec 2018$301.03M+94.7%100.0%-114.1%-120.2%
    Dec 2017$154.58M+2751.6%100.0%-111.0%-32.8%
    Dec 2016$5.42MN/A100.0%-4920.3%-4930.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.20B$1.90B$1.24B$933.01M$701.89M$540.10M$380.83M$301.03M$154.58M$5.42M
    Gross profit$2.20B$1.90B$1.24B$933.01M$701.89M$540.10M$380.83M$301.03M$154.58M$5.42M
    Research and development$1.52B$804.52M$877.39M$877.09M$771.18M$722.34M$734.15M$401.84M$166.71M$188.27M
    Operating income-$699.78M$218.08M-$267.82M-$536.20M-$459.71M-$564.16M-$705.56M-$343.63M-$171.64M-$266.73M
    Net income-$713.41M$235.24M-$535.98M-$703.49M-$418.78M-$554.13M-$715.08M-$361.92M-$50.69M-$267.26M
    EBITDA-$674.57M$298.50M-$88.37M-$522.66M-$380.93M-$526.15M-$689.38MN/A-$41.42M-$261.57M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$381.35M$401.25M$730.80M$442.93M$399.36M$611.09M$744.86M$658.41M$467.17M$362.93M$413.46M$396.78M
    Gross profit$381.35M$401.25M$730.80M$442.93M$399.36M$611.09M$744.86M$658.41M$467.17M$362.93M$413.46M$396.78M
    Operating income-$9.04M$13.29M$358.43M-$411.58M-$103.39M$115.58M-$300.39M$161.68M$22.20M-$701.00K$34.91M$24.63M
    Net income-$28.46M-$4.89M$330.96M-$282.85M-$50.57M$196.89M-$447.51M$159.05M$33.61M$6.46M$36.12M$45.66M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $828.97M exceeded cash and equivalents by $27.69M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$3.35B$3.96B$3.26B$3.13B$3.15B$2.98B$1.82B$1.64B$1.31B$424.10M
    Current assets$2.54B$3.07B$2.58B$2.56B$2.60B$2.49B$1.47B$1.43B$1.23B$373.48M
    Cash and equivalents$801.28M$1.10B$428.43M$966.78M$2.12B$1.50B$835.08M$370.83M$599.69M$122.42M
    Total liabilities$2.21B$2.44B$2.41B$2.74B$2.22B$2.22B$1.00B$609.80M$518.75M$87.41M
    Short-term debt$0$13.47M$105.48M$0$271.70M$193.55M$7.85M$134.09M$6.17M$10.11M
    Long-term debt$828.97M$1.14B$1.13B$1.54B$1.10B$992.49M$681.90M$420.55M$424.88M$6.04M
    Shareholder equity$1.14B$1.53B$859.34M$384.95M$928.01M$761.76M$818.19M$1.03B$789.22M$336.69M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$3.17B$3.19B$3.18B$3.35B$3.49B$3.68B$3.47B$3.96B$3.60B$3.42B$3.22B$3.26B
    Total liabilities$1.64B$1.66B$1.67B$2.21B$2.17B$2.32B$2.32B$2.44B$2.38B$2.35B$2.26B$2.41B
    Cash and equivalents$472.76M$571.15M$464.45M$801.28M$613.08M$510.60M$240.87M$1.10B$197.85M$383.62M$427.29M$428.43M
    Shareholder equity$1.53B$1.53B$1.51B$1.14B$1.32B$1.36B$1.14B$1.53B$1.22B$1.08B$961.19M$859.34M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$205.48M-$205.79M-$500.99M-$325.35M-$443.17M$107.47M-$456.46M-$388.66M-$232.00M-$245.82M
    Capital expenditures$101.97M$136.96M$76.11M$30.82M$38.49M$82.20M$59.63M$61.16M$12.00M$5.34M
    Free cash flow-$307.45M-$342.74M-$577.10M-$356.17M-$481.66M$25.26M-$516.09M-$449.82M-$244.00M-$251.16M
    Dividends paidN/AN/AN/AN/AN/A$286.31M$240.60MN/A$0$0
    Share repurchases$27.40M$0$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow$69.64M$755.56M-$165.80M-$1.05B$495.41M-$121.72M$286.73M-$370.49M-$178.81M-$90.19M
    Financing cash flow-$168.34M$124.81M$125.00M$232.51M$561.57M$682.32M$642.55M$530.15M$888.08M$378.13M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$59.97M$197.07M-$202.68M$131.21M-$14.59M$261.34M-$583.44M$92.05M-$70.70M$14.94M-$242.08M-$54.66M
    Capital expenditures$2.93M$555.00K$2.08M$3.59M$22.93M$31.80M$43.65M$38.08M$37.26M$29.17M$32.44M$19.04M
    Free cash flow$57.03M$196.51M-$204.76M$127.61M-$37.52M$229.54M-$627.09M$53.96M-$107.96M-$14.22M-$274.52M-$73.70M
    Last 12 quarters

    Frequently Asked Questions About SRPT

    What is Sarepta Therapeutics' annual revenue?

    Sarepta Therapeutics reported revenue of $2.20B for the fiscal year ended Dec 31, 2025.

    How fast is Sarepta Therapeutics' revenue growing?

    Revenue was up 15.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 33.1%.

    Is Sarepta Therapeutics profitable?

    No. Sarepta Therapeutics reported net income of -$713.41M for the fiscal year ended Dec 31, 2025, with a net margin of -32.5%.

    How much free cash flow does SRPT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$205.48M minus capital expenditures of $101.97M produced free cash flow of -$307.45M.

    How much debt does Sarepta Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $828.97M, short-term debt of $0 and cash and equivalents of $801.28M.